Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in North Macedonia is experiencing steady growth in recent years.
Customer preferences: In North Macedonia, there is a high demand for antiviral drugs due to the increasing prevalence of viral infections, such as hepatitis, HIV, and influenza. Customers are more inclined towards antiviral drugs that have high efficacy and minimal side effects. They also prefer drugs that are affordable and easily accessible.
Trends in the market: The Antiviral Drugs market in North Macedonia is witnessing a shift towards the development of new and innovative antiviral drugs. There is a growing trend of using combination therapy, which involves the use of two or more antiviral drugs to treat viral infections. This approach is highly effective in preventing the development of drug resistance. Additionally, there is a trend towards the development of antiviral drugs that can be administered orally, as opposed to the traditional injectable drugs.
Local special circumstances: North Macedonia is a small country with a relatively low GDP. As a result, the government has limited resources to spend on healthcare. This has led to a lack of funding for research and development in the pharmaceutical industry. However, there is a growing trend towards public-private partnerships, which are aimed at promoting the development of new drugs and improving access to healthcare.
Underlying macroeconomic factors: North Macedonia is a developing country with a growing economy. The healthcare sector is undergoing significant changes, with a focus on improving the quality of care and increasing access to healthcare services. Additionally, there is a growing trend towards the liberalization of the pharmaceutical industry, which is aimed at promoting competition and improving access to affordable drugs. These factors are expected to drive the growth of the Antiviral Drugs market in North Macedonia in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
